ARRJF:OTC-Arjo AB (publ) (USD)

COMMON STOCK | Medical Distribution | OTC

Last Closing Price

USD 7.00

Change

0.00 (0.00)%

Market Cap

USD 1.91B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ARRJF Stock Forecast & Price:
Based on the Arjo AB (publ) stock forecasts from 0 analysts, the average analyst target price for Arjo AB (publ) is not available over the next 12 months. Arjo AB (publ)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Arjo AB (publ) is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Arjo AB (publ)’s stock price was USD 7.00. Arjo AB (publ)’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -32.20% over the last year.

No recent analyst target price found for Arjo AB (publ)
No recent average analyst rating found for Arjo AB (publ)

About Arjo AB (publ) (ARRJF:OTC)

Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SHPMY Shanghai Pharmaceuticals Holdi..

N/A

USD8.77B 6.69 0.95
SHPMF Shanghai Pharmaceuticals Holdi..

N/A

USD8.25B 6.27 0.95
SHTDF Sinopharm Group Co. Ltd

N/A

USD7.05B 6.05 0.44
SHTDY SINOPHARM GROUP CO LTD ADR

N/A

USD7.04B 6.10 0.44
CAKFF McKesson Europe AG

N/A

USD5.48B 25.10 32.96
CAKFY McKesson Europe AG ADR

N/A

USD4.08B 25.00 32.96
MAHLY Medipal Holdings Corp ADR

N/A

USD3.01B 13.74 0.02
CQCQ MakingORG Inc

N/A

USD0.03B N/A 1,455.17
PDRX Pd-Rx Pharmaceutical

N/A

USD6.09M 3.29 N/A
EXHI Exlites Holdings International..

N/A

USD4.60M N/A N/A

ETFs Containing ARRJF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Distribution)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.57% 23% F 28% F
Dividend Return 10.09% 100% A+ 81% B-
Total Return -28.48% 29% F 36% F
Trailing 12 Months  
Capital Gain -32.20% 67% D+ 45% F
Dividend Return 11.14% 100% A+ 79% C+
Total Return -21.07% 80% B- 52% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 33.02% 87% B+ 69% D+
Dividend Return 1.07% 38% F 25% F
Total Return 34.08% 87% B+ 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 34.62% 47% F 62% D-
Risk Adjusted Return 98.44% 100% A+ 98% A+
Market Capitalization 1.91B 53% F 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Distribution)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.43 9% F 20% F
Price/Book Ratio 2.66 18% F 33% F
Price / Cash Flow Ratio 1.10 50% F 38% F
EV/EBITDA 0.81 43% F 39% F
Management Effectiveness  
Return on Equity 9.57% 75% C 61% D-
Return on Invested Capital 10.43% 69% D+ 69% D+
Return on Assets 4.12% 71% C- 76% C
Debt to Equity Ratio 1.71% 100% A+ 77% C+
Technical Ratios  
Dividend Yield 1.66% 11% F 18% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.15 67% D+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector